TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15853108

Group type: EXPERIMENTAL
Intervention: Chemical-cured Panavia 21
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dual-cured RelyX-ARC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chemical-cured RelyX (resin-modified glass-ionomer cement)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fatigue loading (10^6 load cycles)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no fatigue loading)
Number of subjects: 24
Study: 12429189

Group type: EXPERIMENTAL
Intervention: Five-digit grasping in PD patients
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Five-digit grasping in PD patients with action tremor (AT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 9
Study: 10490156

Group type: EXPERIMENTAL
Intervention: 50 microg fentanyl in 20 ml saline
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 3 mg morphine in 20 ml saline
Number of subjects: 69

Group type: COMPARATOR
Intervention: 20 ml saline (control)
Number of subjects: 69
Study: 8959630

Group type: EXPERIMENTAL
Intervention: Freeline Solo (FS, twin-bag)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Basic Y (BY, single-bag)
Number of subjects: 63
Study: 1822216

Group type: EXPERIMENTAL
Intervention: Diltiazem preparations
Number of subjects: 12
Study: 6309993

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (10 mg Sb/kg per dose) every 12 hr for 15 days (group B)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (10 mg Sb/kg per dose) administered once daily for 31 days (group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (10 mg Sb/kg per dose) every 8 hr for 10 days (group C)
Number of subjects: 29
Study: 31271585

Group type: EXPERIMENTAL
Intervention: Aquatic exercise program (12 weeks, 2 sessions/week, 45 min/session, low intensity)
Number of subjects: 16
Study: 29260804

Group type: EXPERIMENTAL
Intervention: NTP (nonthermal plasma of hexamethyldisiloxane (HMDSO) associated with argon for 30 min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HF + S (10% hydrofluoric acid gel for 60 s and silane for 60 s)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: S (70% alcohol and silane for 60 s)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Co (control, no surface treatment)
Number of subjects: 12
Study: 27604792

Group type: COMPARATOR
Intervention: Education-only intervention (1 onsite education session and distribution of the ART)
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (2 or more onsite education sessions, distribution of the ART, audit and feedback, barrier identification, site-specific strategy development, promotion of interdisciplinary teamwork, opinion leaders and reminders)
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Post-intervention assessment
Number of subjects: 586
Study: 24934963

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg plus adapalene 0.1%/benzoyl peroxide 2.5% gel (D+A/BPO)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Oral isotretinoin (ISO)
Number of subjects: 266
Study: 23019316

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Training (AT/RT)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Training (AT/RT)
Number of subjects: 119
Study: 19602518

Group type: EXPERIMENTAL
Intervention: Individual dose of rFSH (50-100 IU/day)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard dose of rFSH (75 IU/day)
Number of subjects: 228
Study: 17888161

Group type: EXPERIMENTAL
Intervention: Individually tailored worksite health promotion programme with access to an individual Health Portal (features include computer-tailored advice, monitoring function, personal coach, and opportunities to contact professionals).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard worksite health promotion program (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individually tailored worksite health promotion programme.
Number of subjects: 0
Study: 15390018

Group type: EXPERIMENTAL
Intervention: NS 2330
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: NS 2330 with levodopa
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 11289350

Group type: EXPERIMENTAL
Intervention: T4N5 liposome lotion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo liposome lotion
Number of subjects: 30
Study: 9679359

Group type: EXPERIMENTAL
Intervention: Active group (AcuSlim device attached to acupuncture ear points shenmen and stomach)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (AcuSlim device attached to thumb)
Number of subjects: 60
Study: 8018006

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin calcium ointment
Number of subjects: 68
Study: 2920497

Group type: EXPERIMENTAL
Intervention: Adaptive control dosing of etoposide (dose adjustment at 28 hours based on 24-hour plasma level)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard dosing of etoposide (125 mg/m2/day)
Number of subjects: 31
Study: 30212951

Group type: EXPERIMENTAL
Intervention: Prophylactic oral ibuprofen (10, 5, and 5 mg/kg from days 1 to 3 after birth)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional ibuprofen treatment (same dosage from days 4 to 6 after echocardiographic confirmation of PDA on day 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (5% glucose)
Number of subjects: 0
Study: 28106306

Group type: EXPERIMENTAL
Intervention: Group exercise plus acupuncture
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Group exercise plus electro-acupuncture
Number of subjects: 227

Group type: COMPARATOR
Intervention: Group exercise (control)
Number of subjects: 227
Study: 26220293

Group type: EXPERIMENTAL
Intervention: Thawed plasma (TP) administered in-field (2 units)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Thawed plasma (TP)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 210
Study: 23935129

Group type: EXPERIMENTAL
Intervention: 40,000 IU vitamin D/week for 6 months
Number of subjects: 0
Study: 20300016

Group type: EXPERIMENTAL
Intervention: L-Arg/L-Orn supplementation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 17
Study: 17715466

Group type: EXPERIMENTAL
Intervention: Individualised vestibular rehabilitation programme designed by a physiotherapist
Number of subjects: 32

Group type: COMPARATOR
Intervention: Strength and endurance exercises only (Control)
Number of subjects: 32
Study: 17196132

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg once a day for 12 weeks, followed by 36 weeks of ADV
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo once a day for 12 weeks, followed by 36 weeks of ADV
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Lamivudine (LMV) 100 mg + Adefovir dipivoxil (ADV) 10 mg once a day for 12 weeks, followed by 36 weeks of ADV
Number of subjects: 230

Group type: COMPARATOR
Intervention: Lamivudine (LMV) 100 mg + Placebo once a day for 12 weeks, followed by 36 weeks of ADV
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Serum creatinine levels
Number of subjects: 230
Study: 15333417

Group type: EXPERIMENTAL
Intervention: HES 130 (10 mL/kg IV for 30 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HES 200 (10 mL/kg IV for 30 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (10 mL/kg IV for 30 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All test infusions (HES 130, HES 200, Lactated Ringer's)
Number of subjects: 0
Study: 11552898

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9266259

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Exogenous G-CSF substitution protocols
Number of subjects: 59
Study: 8388285

Group type: EXPERIMENTAL
Intervention: Cimetidine suspension 200 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3712165

Group type: COMPARATOR
Intervention: Group 1: 2.24 gm/kg/day protein and 115 kcal/kg/day energy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 2: 3.6 gm/kg/day protein and 115 kcal/kg/day energy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 3: 3.5 gm/kg/day protein and 149 kcal/kg/day energy
Number of subjects: 0
Study: 29576347

Group type: EXPERIMENTAL
Intervention: Antibiotics treatment for intestinal pathogens
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Presence of stool pathogens after clinical stabilization
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Presence of stool pathogens
Number of subjects: 47
Study: 26612275

Group type: EXPERIMENTAL
Intervention: Qualitative interviews during pregnancy and 4 times postpartum
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 10
Study: 25325491

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 335
Study: 22537070

Group type: EXPERIMENTAL
Intervention: 10 g/d BSP
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 5 g/d BSP
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 20458453

Group type: EXPERIMENTAL
Intervention: Rapydan patch (lidocaine-tetracaine)
Number of subjects: 200

Group type: COMPARATOR
Intervention: EMLA patch (lidocaine-prilocaine)
Number of subjects: 200
Study: 19119431

Group type: EXPERIMENTAL
Intervention: Hib polysaccharide conjugated to the tetanus toxoid (PRP-T)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Hib polysaccharide conjugated to the outer‐membrane protein of Neisseria meningitides (PRP-OMP)
Number of subjects: 319
Study: 16448551

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (5-FU, cisplatin, carboplatin, mitomycin C) with radiotherapy (RT)
Number of subjects: 10225

Group type: EXPERIMENTAL
Intervention: 5-FU with RT
Number of subjects: 10225

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy with RT
Number of subjects: 10225

Group type: EXPERIMENTAL
Intervention: Carboplatin-based chemotherapy with RT
Number of subjects: 10225

Group type: EXPERIMENTAL
Intervention: Mitomycin C-based chemotherapy with RT
Number of subjects: 10225

Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy (HFRT)
Number of subjects: 10225

Group type: COMPARATOR
Intervention: Accelerated radiotherapy (AFRT)
Number of subjects: 10225
Study: 14661322

Group type: EXPERIMENTAL
Intervention: Midazolam 0.06 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diazepam 0.12 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Luminal 3 mg/kg
Number of subjects: 60
Study: 11032592

Group type: EXPERIMENTAL
Intervention: Long-term tamoxifen treatment (12-13 years)
Number of subjects: 3793

Group type: COMPARATOR
Intervention: Short-term tamoxifen treatment (2-3 years)
Number of subjects: 3793

Group type: EXPERIMENTAL
Intervention: Long-term tamoxifen treatment (12-13 years) in node-positive patients
Number of subjects: 3793

Group type: EXPERIMENTAL
Intervention: Long-term tamoxifen treatment (12-13 years) in estrogen receptor-positive patients
Number of subjects: 3793

Group type: EXPERIMENTAL
Intervention: Long-term tamoxifen treatment (12-13 years) in estrogen receptor-negative patients
Number of subjects: 3793
Study: 8772625

Group type: EXPERIMENTAL
Intervention: Oral propafenone, mean dose of 615 ± 10 mg day-1
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral quinidine, mean dose of 1067 ± 462 mg day-1
Number of subjects: 48
Study: 1482282

Group type: EXPERIMENTAL
Intervention: Clomipramine (specific serotonin reuptake inhibitor)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Desipramine (tricyclic antidepressant)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3883971

Group type: EXPERIMENTAL
Intervention: Levobunolol hydrochloride 0.5%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Levobunolol hydrochloride 1%
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 42
Study: 30473018

Group type: EXPERIMENTAL
Intervention: Neck-specific training program
Number of subjects: 144

Group type: COMPARATOR
Intervention: Prescribed physical activity
Number of subjects: 144
Study: 27000097

Group type: EXPERIMENTAL
Intervention: Hartcoach (telephonic coaching every four weeks for six months)
Number of subjects: 374
Study: 24108433

Group type: EXPERIMENTAL
Intervention: FRAX tool and pharmacist education on risks of low bone mass
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (heel ultrasound and pharmacist education without FRAX)
Number of subjects: 87
Study: 22893497

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (SET) on top of best medical treatment (BMT) for 6 months
Number of subjects: 53

Group type: COMPARATOR
Intervention: Best medical treatment (BMT) only
Number of subjects: 53
Study: 19224355

Group type: EXPERIMENTAL
Intervention: Vaginal moisturizer (VM) used during coital events for a 4 week period
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaginal microbicides
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Incorporating men into microbicide promotion efforts
Number of subjects: 40
Study: 18317710

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention during the last half of pregnancy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 31
Study: 15665713

Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine coadministered with 7vPn vaccine
Number of subjects: 345

Group type: COMPARATOR
Intervention: DTPa-HBV-IPV/Hib vaccine alone
Number of subjects: 345
Study: 12043288

Group type: EXPERIMENTAL
Intervention: Nerve Fiber Analyser (NFA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 0
Study: 10442525

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Epinastine 20 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7598141

Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contrast venography
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 30
Study: 2242793

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 suppositories 2.5 mg 1‐2 a day
Number of subjects: 91

Group type: COMPARATOR
Intervention: i.v. oxytocin 4‐32 mU/min
Number of subjects: 91
Study: 321170

Group type: EXPERIMENTAL
Intervention: Intravenous iron (iron dextran, 100 mg elemental iron)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral iron (ferrous sulphate, 100 mg elemental iron)
Number of subjects: 0
Study: 31741350

Group type: EXPERIMENTAL
Intervention: Picosecond laser treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lightening cream (control)
Number of subjects: 10
Study: 29268740

Group type: EXPERIMENTAL
Intervention: GABAergic stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-2-adrenergic antagonism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25775435

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 23860050

Group type: EXPERIMENTAL
Intervention: Early feeding (mean time of first oral feeding 2.5 + 0.7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late feeding (mean time of first oral feeding 5.3 + 0.6 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (no mortality reported)
Number of subjects: 0
Study: 21869636

Group type: EXPERIMENTAL
Intervention: Wobble board balance training for 9 weeks, twice a week
Number of subjects: 23
Study: 19700345

Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 110
Study: 17721777

Group type: EXPERIMENTAL
Intervention: Hamstring tendon graft (group H)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bone‐patellar tendon‐bone graft (group B)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 96
Study: 10642363

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise with vascular occlusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-intensity resistance exercise without occlusion (control)
Number of subjects: 6
Study: 8857654

Group type: EXPERIMENTAL
Intervention: 0.25 g fluoride dentifrice
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1.0 g fluoride dentifrice
Number of subjects: 10
Study: 1380721

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Diltiazem and Iloprost
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 6303690

Group type: EXPERIMENTAL
Intervention: 50 micrograms/hr device
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 micrograms/hr device
Number of subjects: 15
Study: 31444036

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 267

Group type: COMPARATOR
Intervention: fMRI measures
Number of subjects: 267

Group type: COMPARATOR
Intervention: Differential fear conditioning
Number of subjects: 267

Group type: COMPARATOR
Intervention: Differential fear learning
Number of subjects: 267
Study: 28548455

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Formalization and professionalization of PSW role
Number of subjects: 21
Study: 26775268

Group type: EXPERIMENTAL
Intervention: dl-3-n-butylphthalide (NBP) for 30 days
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (basic antiplatelet and lipid-lowering therapy only)
Number of subjects: 170
Study: 23742103

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVTA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab
Number of subjects: 26
Study: 22516525

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic treatment (diet and fluid restriction)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic treatment (daily weighing)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic treatment (exercise)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Educational support
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: New approaches to help patients stay physically active
Number of subjects: 648
Study: 20200383

Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 453
Study: 18628451

Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixabepilone as monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 0
Study: 15952179

Group type: EXPERIMENTAL
Intervention: Basic communication skills training program
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Basic communication skills training program followed by consolidation workshops
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Physicians' detection of patients' distress
Number of subjects: 58
Study: 11836283

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE, 200 mg im weekly)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate plus depot medroxyprogesterone acetate (DMPA, 300 mg im once)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (5 men)
Number of subjects: 30
Study: 10433577

Group type: EXPERIMENTAL
Intervention: Chromatographically purified rabies vaccine (CPRV) 0.5 mL
Number of subjects: 400

Group type: COMPARATOR
Intervention: Human diploid cell rabies vaccine (HDCV) 1.0 mL
Number of subjects: 400
Study: 7672551

Group type: EXPERIMENTAL
Intervention: Large capacity biopsy forceps (needle version)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Large capacity biopsy forceps (non-needle version)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Needle versions of each forceps
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard biopsy forceps (needle version)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard biopsy forceps (non-needle version)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Large capacity forceps
Number of subjects: 50
Study: 2206065

Group type: EXPERIMENTAL
Intervention: Intravenous mezlocillin for 48 hours followed by oral ampicillin until delivery
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intravenous and oral placebo
Number of subjects: 85
Study: 31578073

Group type: EXPERIMENTAL
Intervention: careHPV
Number of subjects: 7138

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 7138
Study: 30413383

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Upfront debulking surgery
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (stage IV)
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Upfront debulking surgery (stage IV)
Number of subjects: 1220
Study: 27117874

Group type: EXPERIMENTAL
Intervention: Single dose of 12 mg oral dexamethasone with 4 days of placebo
Number of subjects: 376

Group type: COMPARATOR
Intervention: 5-day course of oral prednisone 60 mg a day
Number of subjects: 376
Study: 25250614

Group type: EXPERIMENTAL
Intervention: LX‐A
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LX‐P
Number of subjects: 20
Study: 23013843

Group type: EXPERIMENTAL
Intervention: DiAlert intervention (two group sessions)
Number of subjects: 21
Study: 20714145

Group type: EXPERIMENTAL
Intervention: Biapenem 300 mg
Number of subjects: 216

Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg/500 mg
Number of subjects: 216